irinotecan has been researched along with vorinostat in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Artali, R; Bianchino, E; Cardile, F; Cincinelli, R; Colelli, F; Dallavalle, S; Guglielmi, M; Musso, L; Pisano, C | 1 |
| Chen, Y; Li, J; Lu, W; Shen, Q; Su, M; Yu, X; Zhang, Q; Zhou, Y; Zhu, Q | 1 |
| Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
| Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S | 1 |
| Chinnaiyan, P; Kahali, S; Sarcar, B | 1 |
| Brem, S; Chinnaiyan, P; Chowdhary, S; Kahali, S; Murtagh, R; Pan, E; Potthast, L; Prabhu, A; Rojiani, A; Sarcar, B; Tsai, YY; Yu, HM | 1 |
| Hoffmann, OI; Ilmberger, C; Jauch, KW; Joka, M; Magosch, S; Mayer, B | 1 |
| Collier, AB; Gresh, RC; Kamara, DF; Kolb, EA; Sampson, VB; Vetter, NS | 1 |
| Berkovich, R; Cohn, SL; Czarnecki, S; DuBois, SG; Goldsmith, KC; Goodarzian, F; Granger, MM; Groshen, S; Haas-Kogan, DA; Irwin, MS; Ji, L; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Park, JR; Pinto, N; Shamirian, A; Shimada, H; Shusterman, S; Tsao-Wei, D; Twist, CJ; Villablanca, JG; Vo, KT; Weiss, B; Yanik, GA | 1 |
2 review(s) available for irinotecan and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
2 trial(s) available for irinotecan and vorinostat
| Article | Year |
|---|---|
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxamic Acids; Insulin-Like Growth Factor Binding Protein 5; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Proteomics; Vorinostat | 2012 |
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neuroblastoma; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vincristine; Vorinostat; Young Adult | 2021 |
8 other study(ies) available for irinotecan and vorinostat
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cells, Cultured; Disulfides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tyrosine | 2018 |
A series of camptothecin prodrugs exhibit HDAC inhibition activity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Stability; HCT116 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Isoenzymes; Mice; Prodrugs; Structure-Activity Relationship | 2018 |
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspases; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Fibroblasts; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Liver Neoplasms; Membrane Potentials; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Skin; Tumor Cells, Cultured; Vorinostat | 2005 |
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Proliferation; Comet Assay; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Synergism; Fluorescent Antibody Technique; Glioblastoma; Humans; Hydroxamic Acids; Irinotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vorinostat | 2010 |
Impact of the spheroid model complexity on drug response.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cetuximab; Coculture Techniques; Everolimus; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Spheroids, Cellular; Stromal Cells; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Vorinostat | 2015 |
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; G1 Phase Cell Cycle Checkpoints; Heterocyclic Compounds, 3-Ring; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sarcoma, Ewing; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53; Vorinostat | 2015 |